OKUR — Onkure Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $37.61m
- -$45.76m
- 17
- 52
- 32
- 23
Annual income statement for Onkure Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 19.6 | 39.8 | 53.8 | 83.1 | 54.4 |
| Operating Profit | -19.6 | -39.8 | -53.8 | -83.1 | -54.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -19.5 | -39.8 | -52 | -77.4 | -52.7 |
| Net Income After Taxes | -19.5 | -39.8 | -52 | -77.4 | -52.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -19.5 | -39.8 | -52 | -77.4 | -52.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -19.5 | -39.8 | -52 | -77.4 | -52.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -8.04 | -16.3 | -21.2 | -25.2 | -15.3 |
| Dividends per Share |